Vanguard Personalized Indexing Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.39M | Buy |
11,035
+2,577
| +30% | +$324K | 0.02% | 710 |
|
|
2025
Q1 | $935K | Sell |
8,458
-2,622
| -24% | -$290K | 0.01% | 823 |
|
|
2024
Q4 | $1.51M | Buy |
11,080
+1,809
| +20% | +$247K | 0.02% | 576 |
|
|
2024
Q3 | $1.07M | Buy |
9,271
+207
| +2% | +$23.9K | 0.02% | 736 |
|
|
2024
Q2 | $1.23M | Buy |
9,064
+326
| +4% | +$44.4K | 0.02% | 587 |
|
|
2024
Q1 | $1.21M | Sell |
8,738
-2,117
| -20% | -$292K | 0.03% | 572 |
|
|
2023
Q4 | $1.43M | Sell |
10,855
-2,253
| -17% | -$297K | 0.04% | 470 |
|
|
2023
Q3 | $1.47M | Buy |
13,108
+786
| +6% | +$88.4K | 0.04% | 399 |
|
|
2023
Q2 | $1.16M | Buy |
12,322
+204
| +2% | +$19.2K | 0.04% | 495 |
|
|
2023
Q1 | $1.23M | Buy |
12,118
+453
| +4% | +$45.9K | 0.04% | 437 |
|
|
2022
Q4 | $1.39M | Buy |
11,665
+502
| +4% | +$60K | 0.06% | 385 |
|
|
2022
Q3 | $1.19M | Sell |
11,163
-140
| -1% | -$14.9K | 0.05% | 406 |
|
|
2022
Q2 | $1.1M | Buy |
11,303
+143
| +1% | +$13.9K | 0.05% | 416 |
|
|
2022
Q1 | $1.05M | Buy |
+11,160
| New | +$1.05M | 0.05% | 428 |
|
|
2021
Q4 | – | Sell |
-3,333
| Closed | -$320K | – | 1094 |
|
|
2021
Q3 | $320K | Sell |
3,333
-3,401
| -51% | -$327K | 0.03% | 738 |
|
|
2021
Q2 | $655K | Buy |
+6,734
| New | +$655K | 0.07% | 367 |
|